Related by context. All words. (Click for frequent words.) 70 Long Term Efficacy 68 Combination Treatment 68 Quadrivalent 67 Antiepileptic Drug 66 Pharmacokinetic Study 66 Phase III Trial 65 Controlled Trial 65 Antiviral Activity 65 Randomized Evaluation 65 Non Inferiority 65 Randomized Clinical Trial 64 Schizophrenia Treatment 64 Pivotal Trials 64 Neuroprotective Effects 64 Controlled Study 64 Adverse Event 64 Shows Efficacy 64 Infarct 64 Clinical Efficacy 64 Prospective Multicenter 64 Phase III Clinical Trial 63 Immunogenicity 63 Patients Receiving 63 Retinal Vein Occlusion 63 Treating Chronic 63 Pediatric Patients 63 Prospective Randomized 63 Zenvia Phase III 63 Study Evaluating 63 Hemorrhagic Stroke 63 Intervention Trial 63 Sirolimus Eluting Stent 63 Randomized Controlled Trial 63 Pregnancy Outcomes 63 Symptom Relief 63 JAK Inhibitor 63 Pivotal Trial 63 IND Application 63 Dual Antiplatelet Therapy 63 Percutaneous Tibial Nerve Stimulation 63 Acute Myocardial Infarction 63 Efficacy Endpoints 63 Phase 2b Study 63 Phase III Clinical Trials 62 Clinical Outcomes 62 Demonstrates Efficacy 62 Fondaparinux 62 Relapsing Multiple Sclerosis 62 Efficacy Trial 62 Potent Inhibitor 62 Pivotal Study 62 Interferon Alfa 62 Clinical Outcome 62 HDAC Inhibitor 62 Immunosuppression 62 Investigational Drug 62 Clinical Trial Data 62 Diabetic Patients 62 Phase IIb Clinical Trial 62 Prolongs Survival 62 Phase IIb Trial 62 Protease Inhibitor 62 FDA Approvals 62 Overactive Bladder 62 Clinical Trial Evaluating 62 Treatment Resistant 62 Increased Incidence 62 Clinical Evaluation 62 Monotherapy 61 Pooled Analysis 61 Meta Analysis 61 Clinical Trial Results 61 Reduced Incidence 61 Randomized Controlled 61 Single Dose 61 Treated Patients 61 Radiofrequency Ablation RFA 61 Sustained Efficacy 61 Initiate Clinical Trial 61 NDA Submission 61 Stent Restenosis 61 Phase 2b Clinical Trial 61 Double Blind Randomized 61 Protease Inhibitors 61 Tolerability Study 61 Hepatocellular Carcinoma 61 Patients Treated 61 Dose Response 61 Intravenous Formulation 61 Nebulized 61 Stimulation Therapy 61 Epoetin Alfa 61 Phase Ib Clinical Trial 61 Autologous Stem Cell Transplantation 61 Appears Safe 61 Long Term Outcomes 61 Phase III Pivotal Trial 61 Improves Outcomes 61 Interferon Alpha 61 Regimens 61 Placebo Controlled Trial 60 Diagnostic Criteria 60 Elderly Patients 60 Tiotropium 60 Severe Asthma 60 Randomized Study 60 Cellular Immunotherapy 60 Contrast Echocardiography 60 Hepatotoxicity 60 Valopicitabine NM# 60 Tolerability 60 Drug Candidate 60 Pharmacokinetic 60 Confirms Efficacy 60 Combination Therapy 60 Randomised 60 Fungal Infections 60 Proves Effective 60 Dose Ranging Study 60 Prospective Randomized Trial 60 Pulmonary Arterial Hypertension 60 Package Insert 60 phase IIIb 60 Invasive Fungal Infections 60 Myelodysplastic Syndromes 60 Left Atrial 60 abacavir Ziagen 60 Investigational Treatment 60 Hepatitis B Vaccine 60 Multiple Myeloma Patients 60 EXPAREL ™ 60 Statistically Significant 60 Proven Effective 60 Demonstrates Potent 60 Ranolazine 60 Iron Deficiency Anemia 60 Potent Antiviral Activity 60 Metabolic Efficiency 60 Severe Sepsis 60 See CLINICAL PHARMACOLOGY 60 Lipid Lowering 60 Drug Eluting 60 II Clinical Trial 60 Randomized Controlled Trials 60 Cardiovascular Outcomes 60 Chronic Renal Failure 60 Adjunctive Therapy 60 Heart Failure Patients 60 Phase IIa Clinical Trial 60 fosbretabulin 60 Hemodialysis Patients 60 Plus Ribavirin 60 Neoadjuvant Chemotherapy 60 Cognitive Impairment 60 Rotavirus Vaccine 59 Platelet Inhibition 59 Seasonal Influenza Vaccine 59 Patients Treated With 59 Pneumococcal Vaccine 59 Contrast Agents 59 Myoblast 59 Adjuvant Chemotherapy 59 Metastatic Colorectal Cancer 59 Insulin Glargine 59 Catheter Ablation 59 Anticoagulant 59 Pharmacodynamics 59 Lung Cancer Trial 59 Lupus Erythematosus 59 Aggressive Reduction 59 Oral Cavity 59 Universal Flu Vaccine 59 Topical Treatment 59 Partial Onset Seizures 59 ISTODAX ® 59 Efficacy 59 Is Well Tolerated 59 Diabetic Neuropathy 59 Drug Regimen 59 ORENCIA ® 59 Patient Registry 59 Beta Blocker 59 Demonstrates Sustained 59 Ischemic Stroke 59 Renal Function 59 Coronary Artery Bypass Graft 59 Multicenter Study 59 Phase 2b Trial 59 Phase III Trials 59 Carotid Artery Stenting 59 Novel Mechanism 59 Pivotal Phase III 59 Laryngeal Cancer 59 Advanced Melanoma 59 Skeletal Muscle 59 Anticancer Drug 59 Estrogen Therapy 59 Septic Shock 59 Replacement Therapy 59 Significantly Improved 59 Anticoagulation 59 Phase 2a Trial 59 Meets Primary Endpoint 59 Phase 2a Clinical Trial 59 Newly Diagnosed 59 Anti Tumor 59 Left Ventricular 59 Orthostatic Hypotension 59 RE MODEL 59 HCV Genotype 59 Data Suggest 59 Adjuvant Therapy 59 Combo Therapy 58 Pivotal Clinical Trial 58 Diabetic Nephropathy 58 Confirmatory Phase 58 Cardiogenic Shock 58 Placebo Controlled Study 58 Prevent Stroke 58 Acute Decompensated Heart Failure 58 Adalimumab 58 Hormone Receptor Positive 58 Inhaled Liposomal Ciprofloxacin 58 Hospitalized Patients 58 Carotid Endarterectomy 58 Investigational Agent 58 Successfully Completes Phase 58 Inflammatory Arthritis 58 Lifestyle Intervention 58 Emerging Therapies 58 Knee Osteoarthritis 58 Viral Suppression 58 Acute Ischemic Stroke 58 Therapy Evaluation 58 Demonstrates Significant 58 Urinary Tract Infections 58 Herbal Extract 58 Well Tolerated 58 Symptom Scale 58 Renal Anemia 58 QLT# 58 Allogeneic 58 Multicenter 58 Venous Thromboembolism 58 Reduced Risk 58 Study Demonstrates 58 Moxifloxacin 58 Ozarelix 58 Screening Tool 58 Multicenter Trial 58 Subtypes 58 Gastrointestinal Disorders 58 Preclinical Data 58 Oral Fingolimod 58 Efficacy Results 58 Smallpox Vaccine 58 Stem Cell Treatment 58 Glatiramer Acetate 58 Inflammatory Markers 58 Parathyroid Hormone 58 Cognitive Function 58 Stem Cell Treatments 58 Efficacious 58 Sipuleucel T 58 Osteoporosis Treatment 58 Cardiopulmonary Bypass 58 Transdermal Patch 58 Bioequivalence 58 NSABP B 58 Rheumatoid Arthritis Patients 58 Androgen Deprivation Therapy 58 Outcome Measures 58 Prophylactic Treatment 58 Renal Cancer 58 Pivotal Phase 58 Antiretroviral Therapy 58 MR Angiography 58 Fracture Risk 58 Demonstrates Statistically Significant 58 Patency 58 PRoFESS 58 Phase IIB 58 Pharmacokinetics PK 58 Medication Adherence 58 Community Acquired Pneumonia 58 Kidney Transplant Recipients 58 Interferon Beta 58 Clinical Practice Guideline 58 Expedited Review 58 Hypertensive Patients 58 Ischemic Events 58 Neoplasms 58 Chemotherapeutic Agents 58 Surgical Treatment 58 Adverse Outcomes 58 Zoledronic Acid 58 Adverse Effects 58 Hormonal Therapy 58 Highly Potent 58 Anti Inflammatory Drug 58 Parenteral Nutrition 58 Adenoma Prevention 58 Liver Failure 58 Present Preclinical Data 58 Antitumor 58 Therapeutic Vaccine 58 Antidepressant Treatment 57 Study Shows Significant 57 Double Blind Placebo 57 Atopic Dermatitis 57 Therapeutic Intervention 57 Diabetic Foot Ulcer 57 Infected Patients 57 Patients Undergoing 57 Progenitor Cells 57 Interferon Gamma 57 Bosutinib 57 Treatment Regimens 57 Restenosis 57 Extended Release Formulation 57 Stakeholder Opinions 57 Beneficial Effects 57 Adjuvant Treatment 57 Chronic Sinusitis 57 Clinical Study 57 Investigator Initiated 57 Stent Thrombosis 57 HCV Protease Inhibitor 57 Investigational Compound 57 Initiated Phase 57 Completes Patient Enrollment 57 Aromatase Inhibitors 57 Platelet Function 57 Improve Outcomes 57 Significantly Improves 57 Recurrent Prostate Cancer 57 Potentially Fatal 57 Cardiotoxicity 57 Eluting 57 Anti Tumor Activity 57 Study Showed 57 Antipsychotic 57 Survival Benefit 57 Erectile Dysfunction Drug 57 Estrogen Receptor 57 Previously Treated 57 Pegylated Interferon 57 Kidney Transplant Patients 57 Postmarketing 57 Antiepileptic Drugs 57 Tablet Formulation 57 Invasive Breast Cancer 57 Gout Drug 57 Phase IIIb 57 Improves Survival 57 Kinase Inhibitors 57 Acute Heart Failure 57 Bare Metal Stents 57 Myocardial Perfusion Imaging 57 Biomarker Study 57 Therapeutic Approaches 57 Peginterferon 57 Lung Injury 57 PDUFA Date 57 Antiretroviral Drug 57 Epilepsy Drug 57 Relapsing Remitting Multiple Sclerosis 57 Subgroup Analysis 57 Pafuramidine 57 Platinol ® 57 Preterm Infants 57 Infliximab 57 LUMINATE 57 Hypercholesterolemia 57 Demonstrates Positive 57 Randomized Double Blind 57 Secondary Hyperparathyroidism 57 Pneumococcal Conjugate Vaccine 57 CT Angiography 57 Vertebral Fracture 57 GISSI 57 Treatment Regimen 57 Prophylaxis 57 Beta Blockers 57 Improve Survival 57 Comorbidities 57 Exacerbation 57 Diastolic Heart Failure 57 Phase Ib clinical 57 Insulin Therapy 57 Mycophenolate Mofetil 57 Inhaled Corticosteroids 57 Antiplatelet Therapy 57 Susceptibility Testing 57 Low Incidence 57 Virologic 57 Shows Statistically Significant 57 Advanced Renal Cell 57 Genetic Markers 57 Thromboembolism 57 Fecal Incontinence 57 Disease Progression 57 Therapeutic Efficacy 57 Molecular Mechanism 57 Detection Device 57 Showed Significant 57 Capecitabine 57 Metastatic Melanoma 57 Metastatic Prostate Cancer 57 Cardiovascular Events 57 COPERNICUS 57 Colorectal Cancer Patients 57 Medication Errors 57 Prognostic Significance 57 Analytical Tool 57 Kidney Function 57 Oral Formulation 56 Renal Cell Carcinoma 56 Clinical Study Shows 56 IND Filing 56 Initiates Phase 2b 56 Tyrosine Kinase Inhibitor 56 RE SURGE 56 Risk Stratification 56 Main Outcome Measure 56 Non Responders 56 Erythropoietic 56 Pegylated Liposomal Doxorubicin 56 Enoxaparin 56 Unfractionated Heparin 56 Completes Enrollment 56 Preclinical Study 56 Phase III Pivotal 56 Lupus Drug 56 Radiofrequency Ablation 56 Novel Oral 56 Peripheral Arterial 56 Hematopoietic Stem Cell Transplantation 56 Cocaine Addiction 56 Novel Small Molecule 56 Stenting 56 Chronic Heart Failure 56 Therapeutic Antibody 56 Premature Infants 56 Integrase Inhibitor 56 Bone Mineral Density 56 Oral Mucositis 56 Contraindications 56 Acute Pancreatitis 56 Montelukast 56 Pemetrexed 56 Suicidality 56 Tumor Response 56 Oral Insulin 56 Tigecycline 56 RNAi Therapeutic 56 Juvenile Idiopathic Arthritis 56 Valsartan 56 Multicenter Phase 56 Antiviral Therapy 56 Unmet Medical 56 Antitumor Activity 56 Patient Enrollment 56 Hip Fracture 56 Prolonged Survival 56 Therapeutic Potential 56 Guidelines Issued 56 Expanded Indication 56 Initiates Clinical 56 Bosentan 56 MMR Vaccine 56 Embolic Protection Device 56 Resistant Hypertension 56 Hematological Cancers 56 Osteoporosis Drug 56 Partial Seizures 56 Stakeholder Insight 56 Clostridium difficile Infection 56 Diagnostic Tests 56 Cypher Sirolimus 56 Menstrual Pain 56 Antiplatelet 56 Mimetics 56 SF #v# 56 Osteoarthritis Patients 56 HCV Infection 56 Initiates Clinical Trial 56 Gastric Cancer 56 Chelation Therapy 56 Invasive Pneumococcal Disease 56 Nilotinib 56 Could Save Lives 56 Therapeutic Effects 56 Skin Lesions 56 AZILECT R 56 Pivotal Phase II 56 Bivalirudin 56 Adverse Reactions 56 Study Reinforces 56 Myocardial Ischemia 56 Observational Study 56 Radiation Induced 56 Suicidal Ideation 56 Shows Promising 56 Potent Anti 56 Treatment Approaches 56 Cloretazine 56 Bare Metal Stent 56 Chemotherapy Induced 56 Mouse Model 56 Statin Therapy 56 Musculo Skeletal Disorders 56 Bevacizumab 56 Bacteremia 56 Reduce Mortality 56 BAL# [002] 56 Melphalan 56 Virus Infection 56 Systematic Review 56 Prolongs Life 56 Stent Implantation 56 Postoperative Pain 56 STRIDE PD 56 Follicular Lymphoma 56 Protein Linked 56 satraplatin Phase 56 Periodontal Disease 56 Drug Eluting Stents 56 Trial Evaluating 56 Data Indicate 56 Chronic Myeloid Leukemia 56 Low Dose 56 CERVARIX 56 Darbepoetin Alfa 56 Proton Pump Inhibitors 56 Drug Resistant 56 Patient Outcomes 56 Antiviral Drugs 56 Uric Acid 56 Corticosteroid 56 Elagolix 56 Antipsychotic Drug 56 Eculizumab 56 Genetic Marker 56 GOUT 56 Therapy Reduces 56 Systemic Sclerosis 56 Implantable Device 56 Antipsychotic Drugs 56 TRANSFORMS 56 Balloon Angioplasty 56 Phase Ib II 56 Pluripotent Stem Cells 56 Valve Replacement 55 Betaferon R 55 Demonstrate Significant 55 Oncolytic 55 Better Outcomes 55 Dosing Regimen 55 Coronary Artery Bypass Surgery 55 Multiple Ascending Dose 55 Topical Gel 55 Treating Depression 55 Immune Therapy 55 pharmacokinetic PK 55 Natalizumab 55 Tumor Targeting 55 ASSERT 55 Nicotine Vaccine 55 Fewer Side Effects 55 Iron Overload 55 Shows Promise Against 55 LibiGel ® 55 Pegylated 55 Randomized Phase 55 Prognostic Factors 55 Ziprasidone 55 Receptor Agonist 55 Reduces Mortality 55 Non Invasive Treatment 55 efavirenz EFV 55 Individualized Treatment 55 Effective Treatments 55 Iron Deficiency 55 Postmenopausal Osteoporosis 55 Approvable 55 Survival Rate 55 Patients Enrolled 55 Carotid 55 Atypical Antipsychotic 55 Vaccine Candidate 55 Subcutaneous 55 Treatment Naive 55 Induction Therapy 55 Temsirolimus 55 Cervical Spine 55 Kidney Transplants 55 Lipid Levels 55 HPV Vaccine Gardasil 55 Therapy Shows Promise 55 Colorectal Screening 55 Inhibits Growth 55 IIa Clinical Trial 55 Coronary Revascularization 55 Newly Diagnosed Multiple Myeloma 55 Randomised Controlled Trial 55 Localized Prostate Cancer 55 Who Underwent 55 Daptomycin 55 Metabolic Disorder 55 Radical Prostatectomy 55 Blood Pressure Reduction 55 Hormone Refractory Prostate Cancer 55 Safinamide 55 Carotid Stenting 55 Surgical Procedures 55 Neuroprotection 55 Adjunctive Treatment 55 Contraceptive Use 55 Solid Tumors 55 Advanced Colorectal Cancer 55 CHMP Opinion 55 Genes Involved 55 Extended Release 55 Pioglitazone 55 Pharmacokinetic PK 55 Stent Placement 55 Pharmacologic 55 Capsules CII 55 Anticoagulants 55 Surgical Mesh 55 First Patient Dosed 55 Controlled Clinical Trial 55 Herbal Supplements 55 Antihypertensive 55 Thrombotic 55 Unstable Angina 55 Genetic Tests 55 PEG IFN 55 Novel Therapies 55 STENT 55 phase IIa 55 Urinary Catheter 55 Dose Escalation 55 aripiprazole Abilify 55 Total Hip Replacement 55 Lumbar Disc 55 Improved Survival 55 Shown Effective 55 Breast Cancer Recurrence 55 Reduces Risk 55 Lung Cancer Drug 55 ARIXTRA R 55 Node Positive 55 Late Breaker 55 Decitabine 55 rilonacept 55 TB Vaccine 55 Novel Treatments 55 Chronic Constipation 55 Immune Mediated 55 Novel Inhibitor 55 PROCRIT R 55 Assay Kits 55 Current Controlled Trials 55 Immunosuppressant 55 Liver Function 55 Hematopoietic Stem Cells 55 Interventional Procedures 55 Blood Pressure Lowering 55 Presents Preclinical Data 55 Slow Progression 55 Delayed Graft Function 55 Randomized Placebo Controlled Trial 55 Etiology 55 Significant Efficacy 55 Demonstrated Significant 55 Biphasic 55 Secondary Endpoints 55 Advanced Pancreatic Cancer 55 FDA APPROVES 55 LIALDA 55 Begin Clinical Trials 55 Anticancer Activity 55 Hepatitis C Genotype 55 Bioavailability 55 dual endothelin receptor antagonist 55 Preterm Delivery 55 Arterial Disease 55 Allergic Rhinitis 55 Fulvestrant 55 Enzyme Replacement Therapy 55 Panic Disorder 55 Minimally Invasive Treatment 55 Devices Advisory Panel 55 Study Shows Benefits 55 Medoxomil 55 Menopausal Women 55 Increases Risk 55 Endovascular Treatment 55 Patient Populations 55 Male Infertility 55 Differential Diagnosis 55 Malaria Vaccine 54 Protease 54 Artery Disease 54 Viral Load 54 Tanespimycin 54 von Willebrand Factor 54 Files Investigational 54 Naturally Occurring 54 Adjuvant Breast Cancer 54 Short Stature 54 Vaccine Trial 54 Bazedoxifene 54 Anticancer Agent 54 Valproic Acid 54 Inhalation Solution 54 Radioimmunotherapy 54 Nuclear Receptors 54 Based Regimens 54 Aortic Valve Replacement 54 Intravitreal 54 Aortic Stenosis 54 Sevelamer 54 Further Validates 54 GRAS Status 54 Inhaled Nitric Oxide 54 Breast Cancer Treatment 54 Inflammatory Response 54 multicentre randomized double 54 FDA Okays 54 Cardiovascular Disease Risk 54 Peginterferon Alfa 2a 54 Bronchodilator 54 Drug Shows Promise 54 DEFINITIVE AR 54 Study Proves 54 Depressive Symptoms 54 Patients Suffering 54 MOVIPREP ® 54 Eluting Stent 54 Childhood Vaccinations 54 Antibiotic Treatment 54 Prostate Cancer Patients 54 Molecular Basis 54 Multicentre 54 liposome injection 54 preclinical efficacy 54 multicenter phase 54 Nesiritide 54 Peer Reviewed Publication 54 Left Ventricular Dysfunction 54 Coronary Arteries 54 Liver Fibrosis 54 Renal Failure 54 Versus Placebo 54 Clinical Trial 54 Hsp# Inhibitor 54 Rilonacept 54 Fabry Disease 54 Posaconazole 54 Statistical Significance 54 ACE Inhibitor 54 Infusion System 54 Oral Insulin Capsule 54 Hepatic Encephalopathy 54 Darunavir 54 Shingles Vaccine 54 Survival Rates 54 Cognitive Dysfunction 54 Guideline Update 54 Placebo controlled 54 Thrombolytic Therapy 54 Randomized Trials 54 Degarelix 54 Randomized controlled 54 boosted protease inhibitor 54 Prognostic Value 54 Skin Irritation 54 Calcium Acetate 54 Epoetin 54 Mutation Analysis 54 Gene Mutation 54 Predict Response 54 FDA Accepts 54 Lipid Profile 54 Meta Analyses 54 Randomized Trial 54 Cholesterol Drug 54 Dasatinib 54 Novel Therapeutic 54 Migraine Drug 54 Antigen CEA 54 Renal Artery 54 Recurrent Breast Cancer 54 Demonstrates Potential 54 Immunogenic 54 PKC# 54 Allograft 54 Glycemic Control 54 Obese Patients 54 unfractionated heparin UFH 54 Drug Fails 54 Statin Drugs 54 Lung Cancer Treatment 54 ritonavir boosted 54 Treatment Naive Patients 54 Influenza Vaccine Production 54 Primary Endpoint 54 C1 Inhibitor 54 Fatty Liver 54 PRECISE 54 SABCS 54 Chemoradiation 54 Postmenopausal 54 Eluting Coronary Stent System 54 Aneurysm Repair 54 Neoadjuvant 54 Loading Dose 54 Effectively Treats 54 Dalbavancin 54 Cancer Treatments 54 Wound Closure 54 Conjugate 54 Angiogenic 54 ADVANCE PD 54 Antidiabetic 54 ACOMPLIA R 54 Suboptimal 54 Thrombolysis 54 Orally Active 54 Randomized Clinical Trials 54 Cilostazol 54 Tumor Progression 54 Psoriasis Drug 54 Treatment Naive HIV 54 Carotid Stent 54 Pain Relievers 54 BioSante Pharmaceuticals Reports 54 Intravascular 54 Intervention Effectiveness 54 Stable Angina 54 pharmacokinetic PK study 54 Clinical Practice Guidelines 54 Recombinant Human 54 Significantly Reduced 54 HepaSphere 54 Asthma Inhaler 54 Ischemic 54 Treatment Algorithms 54 Cinacalcet 54 Tumor Cell 54 icatibant 54 Asthma Treatment 54 Commonly Used 54 Treatment Naïve 54 Thrombus 54 Novel Antibiotic 54 Longitudinal Assessment 54 inhibitor RG# 54 Chronic Inflammation 54 Malignant Glioma 54 Randomized Placebo controlled 54 uricase 54 Diabetes Complications 54 Relapsed Refractory 54 Ischemic Cardiomyopathy 54 Significant Improvements 54 Erythropoiesis Stimulating Agents 54 ENDEAVOR II 54 Decompensated Heart Failure 54 Achieves Primary Endpoint 54 Blind Placebo Controlled Trial 54 Initiate Phase 54 Stem Cell Transplants 54 Onrigin 54 Psychiatric Disorders 54 Chronic Lymphocytic Leukemia 54 Cyclooxygenase 2 54 Pulmonary Artery 54 Advanced Prostate Cancer 54 Immune Responses 54 Initiate Phase II 54 Reduces Pain 54 Universal Influenza Vaccine 54 Aliskiren 54 CAMMS# 54 Lung Cancer Screening 54 Genes Linked 54 Antibiotic Use 54 placebo controlled Phase III 54 Blood Pressure Drug 54 Childhood Asthma 54 Cell Lymphoma 54 Rheumatoid 54 Generic Versions 54 Oral Fluid 54 Test Detects 54 Breast Density 54 peginterferon alfa 2a #KD 54 Alternative Treatments 54 Sapacitabine 54 Hepatitis C Treatment 54 Antiangiogenic 54 Guidelines Recommend 54 Malignancies 54 Phase IIIb clinical 54 Pharmacodynamic 54 Acute Kidney 54 atazanavir sulfate 54 Synthetic Peptide 54 Study Validates 54 Nocturia 53 Watchful Waiting 53 Pramlintide 53 Receptor Antagonists 53 Clinical Relevance 53 Pandemic Influenza Vaccine 53 Treat Parkinson Disease 53 Clinical Guideline 53 Therapeutic Antibodies 53 Dry Powder Inhaler 53 Testosterone Gel 53 Deep Venous Thrombosis 53 prucalopride 53 Inflammatory Pain 53 Protein Involved 53 Targeted Therapy 53 Cholesterol Levels 53 Anti Depressant 53 Fast Track Status 53 Accelerated Approval 53 Randomized Double blind 53 Chronic Insomnia 53 Febrile Neutropenia 53 Randomized Double Blind Placebo 53 Preclinical Models 53 Biologics Compendium 53 Heart Transplant Recipients 53 TLK# 53 multicenter randomized controlled 53 Antithrombotic 53 Dose Reduction 53 Cost Effectiveness 53 Modifiable 53 Vivo Efficacy 53 Echocardiographic 53 Infarction 53 ENDEAVOR 53 Radiation Dose 53 Cardiomyocytes 53 Epitopes 53 Cethromycin 53 Lung Cancer Survival 53 Study Indicates 53 Nucleoside 53 Autoimmune Diseases 53 Drug Combo 53 Vicriviroc 53 Bipolar Depression 53 Cannabinoid 53 Serious Adverse Events 53 NICE SUGAR 53 Preliminary Findings 53 Feasibility Trial 53 Prodrug 53 KRN# 53 CLARITY TIMI 53 multicentre randomized 53 Novel Compound 53 Microalbuminuria 53 Undergo Mental 53 Multicenter Randomized Double 53 Sequenced Treatment Alternatives 53 Weight Reduction 53 Unapproved Drugs 53 Data Extraction 53 Nonalcoholic Fatty Liver Disease 53 Immunomodulatory 53 multicenter multinational 53 Renal Insufficiency 53 Cardiovascular Risk 53 Small Molecule 53 Functional Dyspepsia 53 Hospital Acquired Pneumonia 53 Cesarean Delivery 53 TNF Alpha 53 Generalized Anxiety Disorder 53 Isomer 53 Adjunctive 53 Non Insulin Dependent 53 HER2 Positive Breast Cancer 53 APTIVUS 53 Teva Provides Update 53 Resection 53 Vildagliptin 53 TAXUS ATLAS 53 Subtype